Helping people with HIV quit tobacco in Kenya
Integrating tobacco use cessation into HIV Care and Treatment in Ministry of Health Facilities in Kisumu County, Kenya
This study is testing a new way to help people living with HIV in Kenya quit smoking by adding support programs right into their regular HIV care, making it easier for them to stop using tobacco and improve their health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10909243 on NIH RePORTER |
What this research studies
This research focuses on integrating tobacco cessation programs into HIV care for individuals living with HIV in Kenya. It aims to address the high rates of tobacco use among this population, which is linked to increased mortality and health complications. By implementing the National Guidelines for Tobacco Dependence Treatment and Cessation in HIV clinics, the project seeks to provide support for quitting tobacco in a primary care setting. The approach involves collaboration with local health services to ensure effective delivery of cessation interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 21 and older living with HIV who also use tobacco.
Not a fit: Patients who do not use tobacco or are under 21 years old may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the health outcomes of people living with HIV by reducing tobacco-related illnesses and mortality.
How similar studies have performed: While there is limited research on integrating tobacco cessation in HIV care in Kenya, similar approaches in other regions have shown promise in improving health outcomes for people living with HIV.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Bialous, Stella Aguinaga — University of California, San Francisco
- Study coordinator: Bialous, Stella Aguinaga
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.